In brief: Peplin, Bone Medical, Probiomics, BioDiem
Monday, 01 August, 2005
Peplin (ASX:PEP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.
Bone Medical (ASX:BNE) has appointed BIO-IB as financial advisors to assist with a potential capital raise targeting US institutional investors expected to take place later this year.
Taylor Collison intends to underwrite a $1 million placement of new fully paid ordinary shares in Probiomics (ASX:PCC). A total of 12,500,000 shares will be issued at $0.08 per share and the funds from the placement will be used for working capital.
BioDiem (ASXBDM) has received its second US$1 million milestone payment under its US$8m licence agreement with Akzo Nobel's Nobilon in the development of its novel intranasal flu vaccine.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
